C4 Therapeutics Statistics
Total Valuation
C4 Therapeutics has a market cap or net worth of $158.71 million. The enterprise value is -$1.34 million.
Important Dates
The next estimated earnings date is Thursday, October 30, 2025, before market open.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
C4 Therapeutics has 71.17 million shares outstanding. The number of shares has increased by 18.67% in one year.
| Current Share Class | 71.17M |
| Shares Outstanding | 71.17M |
| Shares Change (YoY) | +18.67% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 3.25% |
| Owned by Institutions (%) | 58.40% |
| Float | 50.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.59 |
| Forward PS | 8.76 |
| PB Ratio | 0.91 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.06, with a Debt / Equity ratio of 0.36.
| Current Ratio | 5.06 |
| Quick Ratio | 4.87 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.99% and return on invested capital (ROIC) is -27.97%.
| Return on Equity (ROE) | -52.99% |
| Return on Assets (ROA) | -22.80% |
| Return on Invested Capital (ROIC) | -27.97% |
| Return on Capital Employed (ROCE) | -49.04% |
| Revenue Per Employee | $311,273 |
| Profits Per Employee | -$1.01M |
| Employee Count | 110 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, C4 Therapeutics has paid $131,000 in taxes.
| Income Tax | 131,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.38% in the last 52 weeks. The beta is 3.00, so C4 Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 3.00 |
| 52-Week Price Change | -64.38% |
| 50-Day Moving Average | 2.53 |
| 200-Day Moving Average | 2.42 |
| Relative Strength Index (RSI) | 38.70 |
| Average Volume (20 Days) | 1,842,739 |
Short Selling Information
The latest short interest is 3.54 million, so 4.98% of the outstanding shares have been sold short.
| Short Interest | 3.54M |
| Short Previous Month | 3.78M |
| Short % of Shares Out | 4.98% |
| Short % of Float | 7.06% |
| Short Ratio (days to cover) | 2.54 |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of $34.24 million and -$111.58 million in losses. Loss per share was -$1.58.
| Revenue | 34.24M |
| Gross Profit | -83.38M |
| Operating Income | -123.62M |
| Pretax Income | -111.45M |
| Net Income | -111.58M |
| EBITDA | -121.63M |
| EBIT | -123.62M |
| Loss Per Share | -$1.58 |
Full Income StatementBalance Sheet
The company has $214.55 million in cash and $62.92 million in debt, giving a net cash position of $160.05 million or $2.25 per share.
| Cash & Cash Equivalents | 214.55M |
| Total Debt | 62.92M |
| Net Cash | 160.05M |
| Net Cash Per Share | $2.25 |
| Equity (Book Value) | 174.06M |
| Book Value Per Share | 2.45 |
| Working Capital | 180.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$87.41 million and capital expenditures -$168,000, giving a free cash flow of -$87.58 million.
| Operating Cash Flow | -87.41M |
| Capital Expenditures | -168,000 |
| Free Cash Flow | -87.58M |
| FCF Per Share | -$1.23 |
Full Cash Flow StatementMargins
| Gross Margin | -243.52% |
| Operating Margin | -361.03% |
| Pretax Margin | -325.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
C4 Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.67% |
| Shareholder Yield | -18.67% |
| Earnings Yield | -70.30% |
| FCF Yield | -55.18% |
Analyst Forecast
The average price target for C4 Therapeutics is $8.50, which is 281.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.50 |
| Price Target Difference | 281.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 114.21% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
C4 Therapeutics has an Altman Z-Score of -2.44 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.44 |
| Piotroski F-Score | 3 |
